# EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults

> **NCT01026246** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 60 (actual)

## Conditions studied

- Plasmodium Falciparum Malaria

## Interventions

- **DRUG:** Placebo
- **BIOLOGICAL:** EBA-175 RII-NG Malaria Vaccine

## Key facts

- **NCT ID:** NCT01026246
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01026246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01026246, "EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01026246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*